Advanced search
Publication Cover
Expert Review of Dermatology Volume 8, 2013 - Issue 5
Journal homepage
29
Views
4
CrossRef citations to date
0
Altmetric
Reviews

Anti-CTLA-4 and BRAF inhibition in patients with metastatic melanoma and brain metastases

Igor PuzanovDivision of Hematology-Oncology, Vanderbilt-Ingram Cancer Center, 2220 Pierce Avenue, 777 Preston Research Building, Nashville, TN 37232-6307, USACorrespondence[email protected]
,
Jedd D WolchokMemorial Sloan-Kettering Cancer Center, 1275 York Avenue, NY 10021, USA
,
Paolo A AsciertoMelanoma Cancer Immunotherapy and Innovative Therapy Unit, Istituto Nazionale Tumori Fondazione ‘G. Pascale’ Via Mariano Semmola, 80131 Napoli, Italy
,
Omid HamidTranslational Research and Immunotherapy, The Angeles Clinic and Research Institute, 11818 Wilshire Blvd, Suite 200, Los Angeles, CA 90049, USA
&
Kim MargolinFred Hutchinson Cancer Research Center, Seattle Cancer Care Alliance, 825 Eastlake Ave. E, Seattle, WA 98109-1023, USA
Pages 479-487 | Published online: 10 Jan 2014

References

  • Miller AJ, Mihm MC. Melanoma. N. Engl. J. Med. 355(1), 51–65 (2006).
  • Barnholtz-Sloan JS, Sloan AE, Davis FG, Vigneau FD, Lai P, Sawaya RE. Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System. J. Clin. Oncol. 22(14), 2865–2872 (2004).
  • Shapiro DG, Samlowski WE. Management of melanoma brain metastases in the era of targeted therapy. J. Skin Cancer 2011, 845863 (2011).
  • Nieder C, Adam M, Astner ST. Disease presentation and outcome in young patients (<40 years) with brain metastases from malignant melanoma. Anticancer Res. 28(2B), 1325–1327 (2008).
  • Salvati M, Cervoni L, Caruso R, Gagliardi FM. Solitary cerebral metastasis from melanoma: value of the ‘en block’ resection. Clin. Neurol. Neurosurg. 98(1), 12–14 (1996).
  • Goulart CR, Mattei TA, Ramina R. Cerebral melanoma metastases: a critical review on diagnostic methods and therapeutic options. ISRN Surg. 2011, 276908 (2011).
  • Korn EL, Liu PY, Lee SJ et al. Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. J. Clin. Oncol. 26(4), 527–534 (2008).
  • Sampson JH, Carter JHJr, Friedman AH, Seigler HF. Demographics, prognosis, and therapy in 702 patients with brain metastases from malignant melanoma. J. Neurosurg. 88(1), 11–20 (1998).
  • Majer M, Jensen RL, Shrieve DC et al. Biochemotherapy of metastatic melanoma in patients with or without recently diagnosed brain metastases. Cancer 110(6), 1329–1337 (2007).
  • McWilliams RR, Rao RD, Buckner JC, Link MJ, Markovic S, Brown PD. Melanoma-induced brain metastases. Expert Rev. Anticancer Ther. 8(5), 743–755 (2008).
  • Knisely JPS, Yu JB, Flanigan J, Sznol M, Kluger HM, Chiang VL. Radiosurgery for melanoma brain metastases in the ipilimumab era and the possibility of longer survival. J. Neurosurg. 117(2), 227–233 (2012).
  • Fife KM, Colman MH, Stevens GN et al. Determinants of outcome in melanoma patients with cerebral metastases. J. Clin. Oncol. 22(7), 1293–1300 (2004).
  • Hanson PW, Elaimy AL, Lamoreaux WT et al. A concise review of the efficacy of stereotactic radiosurgery in the management of melanoma and renal cell carcinoma brain metastases. World J. Surg. Oncol. 10, 176 (2012).
  • Hofmann MA, Hauschild A, Mohr P et al. Prospective evaluation of supportive care with or without CVD chemotherapy as a second-line treatment in advanced melanoma by patient's choice: a multicentre Dermatologic Cooperative Oncology Group trial. Melanoma Res. 21(6), 516–523 (2011).
  • Avril MF, Aamdal S, Grob JJ et al. Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study. J. Clin. Oncol. 22(6), 1118–1125 (2004).
  • Quirt I, Verma S, Petrella T, Bak K, Charette M. Temozolomide for the treatment of metastatic melanoma: a systematic review. Oncologist 12(9), 1114–1123 (2007).
  • Hwu WJ, Lis E, Menell JH et al. Temozolomide plus thalidomide in patients with brain metastases from melanoma: a phase II study. Cancer 103(12), 2590–2597 (2005).
  • Agarwala SS, Kirkwood JM, Gore M et al. Temozolomide for the treatment of brain metastases associated with metastatic melanoma: a phase II study. J. Clin. Oncol. 22(11), 2101–2107 (2004).
  • Paul MJ, Summers Y, Calvert AH et al. Effect of temozolomide on central nervous system relapse in patients with advanced melanoma. Melanoma Res. 12(2), 175–178 (2002).
  • Margolin K, Atkins B, Thompson A et al. Temozolomide and whole brain irradiation in melanoma metastatic to the brain: a phase II trial of the Cytokine Working Group. J. Cancer Res. Clin. Oncol. 128(4), 214–218 (2002).
  • Hofmann M, Kiecker F, Wurm R et al. Temozolomide with or without radiotherapy in melanoma with unresectable brain metastases. J. Neurooncol. 76(1), 59–64 (2006).
  • Atkins MB, Sosman JA, Agarwala S et al. Temozolomide, thalidomide, and whole brain radiation therapy for patients with brain metastasis from metastatic melanoma: a phase II Cytokine Working Group study. Cancer 113(8), 2139–2145 (2008).
  • Hoos A, Ibrahim R, Korman A et al. Development of ipilimumab: contribution to a new paradigm for cancer immunotherapy. Semin. Oncol. 37(5), 533–546 (2010).
  • Hodi FS, O’Day SJ, McDermott DF et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363(8), 711–723 (2010).
  • Robert C, Thomas L, Bondarenko I et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N. Engl. J. Med. 364(26), 2517–2526 (2011).
  • Lebbé C, McDermott DF, Robert C et al. Ipilimumab improves survival in previously treated, advanced melanoma patients with poor prognostic factors: subgroup analyses from a phase III trial [abstract]. Ann. Oncol. 21( Suppl. 8), viii401 (2010).
  • Heller KN, Pavlick AC, Hodi FS et al. Safety and survival analysis of ipilimumab therapy in patients with stable asymptomatic brain metastases [abstract]. J. Clin. Oncol. 29(15 Suppl.), 8581 (2011).
  • Margolin K, Ernstoff MS, Hamid O et al. Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. Lancet Oncol. 13(5), 459–465 (2012).
  • Di Giacomo AM, Ascierto PA, Pilla L et al. Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial. Lancet Oncol. 13(9), 879–886 (2012).
  • Wolchok JD, Hoos A, O’Day S et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin. Cancer Res. 15(23), 7412–7420 (2009).
  • Hodi FS, Oble DA, Drappatz J et al. CTLA-4 blockade with ipilimumab induces significant clinical benefit in a female with melanoma metastases to the CNS. Nat. Clin. Pract. Oncol. 5(9), 557–561 (2008).
  • Schartz NE, Farges C, Madelaine I et al. Compete regression of a previously untreated melanoma brain metastasis with melanoma. Melanoma Res. 20(3), 247–250 (2010).
  • Davies H, Bignell GR, Cox C et al. Mutations of the BRAF gene in human cancer. Nature 417(6892), 949–954 (2002).
  • Chapman PB, Hauschild A, Robert C et al; and BRIM-3 Study Group. Improved survival with vemurafenib in melanoma with BRAF V200E mutation. N. Engl. J. Med. 364(26), 2507–2516 (2011).
  • Colombino M, Capone M, Lissia A et al. BRAF/NRAS mutation frequencies among primary tumors and metastases in patients with melanoma. J. Clin. Oncol. 30(20), 2522–2529 (2012).
  • Capper D, Berghoff AS, Magerle M et al. Immunohistochemical testing of BRAF V600E status in 1,120 tumor tissue samples of patients with brain metastases. Acta. Neuropathol. 123(2), 223–233 (2012).
  • Jakob JA, Bassett RL, Ng CS et al. NRAS mutation status is an independent prognostic factor in metastatic melanoma. Cancer 118(16), 4014–4023 (2011).
  • Kumar R, Angelini S, Czene K et al. BRAF mutations in metastatic melanoma: a possible association with clinical outcome. Clin. Cancer Res. 9(9), 3362–3368 (2003).
  • Long GV, Menzies AM, Nagrial AM et al. Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. J. Clin. Oncol. 29(10), 1239–1246 (2011).
  • Chapman PB, Hauschild A, Robert C et al. Updated overall survival (OS) results for BRIM-3, a phase III randomized, open-label, multicenter trial comparing BRAF inhibitor vemurafenib (vem) with dacarbazine (DTIC) in previously untreated patients with BRAFV600E-mutated melanoma [abstract]. J. Clin. Oncol. 30(15 Suppl.) 8502 (2012).
  • Sosman JA, Kim KB, Schuchter L et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N. Engl. J. Med. 2012 366(8), 707–714 (2012).
  • Trefzer U, Minor D, Ribas A et al. BREAK-2: a phase IIA trial of the selective BRAF kinase inhibitor GSK2118436 in patients with BRAF mutation-positive (V600E/K) metastatic melanoma [abstract]. Pigment Cell Res. 24, 1020 (2011).
  • Dummer R, Rinderknecht J, Goldinger SM et al. An open-label pilot study of vermurafenib in previously treated metastatic melanoma patients with brain metastases [abstract]. J. Clin. Oncol. 29(15 Suppl.), 8548 (2011).
  • Kefford R, Arkenau H, Brown MP et al. Phase I/II study of GSK2118436, a selective inhibitor of oncogenic mutant BRAF kinase, in patients with metastatic melanoma and other solid tumors [abstract]. J. Clin. Oncol. 28(15 Suppl.), 8503 (2010).
  • Long GV, Kefford RF, Carr PJA et al. Phase 1/2 study of GSK2118436, a selective inhibitor of V600 mutant (mut) BRAF kinase: evidence of activity in melanoma brain metastases (mets). Presented at: 35th European Society for Medical Oncology Congress. Milan, Italy, 8–12 October 2010.
  • Falchook GS, Long GV, Kurzrock R et al. Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. Lancet 379(9829), 1893–1901 (2012).
  • Kirkwood JM, Long GV, Trefzer U et al. BREAK-MB: a phase II study assessing overall intracranial response rate (OIRR) to dabrafenib (GSK2118436) in patients (pts) with BRAF V600E/k mutation-positive melanoma with brain metastases (mets) [abstract]. J. Clin. Oncol. 30(15 Suppl.), 8501 (2012).
  • Long GV, Trefzer U, Davies MA et al. Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. Lancet Oncol. 13(11), 1087–1095 (2012).
  • Hauschild A, Grob JJ, Demidov LV et al. Phase III, randomized, open-label, multicenter trial (BREAK-3) comparing the BRAF kinase inhibitor dabrafenib (GSK2118436) with dacarbazine (DTIC) in patients with BRAFV600E-mutated melanoma [abstract]. J. Clin. Oncol. 30(15 Suppl.), LBA8500 (2012).
  • Dummer R, Goldinger SM, Turtschi CP et al. Open-label pilot study of vemurafenib in previously treated metastatic melanoma (mM) patients (pts) with symptomatic brain metastases (BM). Presented at: 37th European Society for Medical Oncology Congress. Vienna, Austria, 28 September–2 October 2012.
  • Rochet NM, Kottschade LA, Markovic SN. Vemurafenib for melanoma metastases to the brain. N. Engl. J. Med. 365(25), 2439–2441 (2011).
  • Mittapalli RK, Vaidhyanathan S, Sane R, Elmquist WF. Impact of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) on the brain distribution of a novel BRAF inhibitor: vemurafenib (PLX4032). J. Pharmacol. Exp. Ther. 342(1), 33–40 (2012).
  • Mitchell MS. Relapse in the central nervous system in melanoma patients successfully treated with biomodulators. J. Clin. Oncol. 7(11), 1701–1709 (1989).
  • Ma MW, Qian M, Lackaye DJ et al. Challenging the current paradigm of melanoma progression: brain metastasis as isolated first visceral site. Neuro. Oncol. 14(7), 849–858 (2012).
  • Simeone E, De Maio E, Sandomenico F et al. Neoplastic leptomeningitis presenting in a melanoma patient treated with dabrafenib (a V600EBRAF inhibitor): a case report. J. Med. Case Rep. 6(1), 131 (2012).
  • Luke JJ, Hodi FS. A new class of treatment for metastatic melanoma. Clin. Cancer Res. 18(1), 9–14 (2012).
  • Anker CJ, Ribas A, Grossmann AH et al. Severe liver and skin toxicity after radiation and vemurafenib in metastatic melanoma. J. Clin. Oncol. 31(17), e283–287 (2013).
  • Topalian SL, Hodi FS, Brahmer JR et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366(26), 2443–2454 (2012).
  • Brahmer JR, Tykodi SS, Chow LQ et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med. 366(26), 2455–2465 (2012).
  • Wolchok JD, Kluger H, Callahan MK et al. Nivolumab plus ipilimumab in advanced melanoma. N. Engl. J. Med. 369(2), 122–133 (2013).

Websites

  • Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. GLOBOCAN 2008 v2.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10 [Internet]. International Agency for Research on Cancer. Lyon, France. (2010). http://globocan.iarc.fr ( Accessed 17 July 2013)
  • National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology – Melanoma. Version 2 (2013). www.nccn.com ( Accessed 17 July 2013)
  • Bristol-Myers Squibb Company. YERVOY™ (ipilimumab) US Prescribing Information: Risk Evaluation and Mitigation Strategy. c2011 [updated 2011; cited 2012 Mar 17]. www.yervoy.com/hcp/rems.aspx ( Accessed 17 July 2013)

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.